Cargando…

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer

Many clinical trials are being conducted to clarify effective combinations of various drugs for immune checkpoint blockade (ICB) therapy. However, although extensive studies from multiple aspects have been conducted regarding treatments for pancreatic ductal adenocarcinoma (PDAC), there are still no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashimoto, Ari, Handa, Haruka, Hata, Soichiro, Tsutaho, Akio, Yoshida, Takao, Hirano, Satoshi, Hashimoto, Shigeru, Sabe, Hisataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127265/ https://www.ncbi.nlm.nih.gov/pubmed/34001163 http://dx.doi.org/10.1186/s12964-021-00733-y

Ejemplares similares

High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
por: Tsutaho, Akio, et al.
Publicado: (2020)

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)

Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells
por: Handa, Haruka, et al.
Publicado: (2017)

Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
por: Otsuka, Yutaro, et al.
Publicado: (2018)

KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
por: Sabe, Hisataka
Publicado: (2023)

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2016)

P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance
por: Hashimoto, Ari, et al.
Publicado: (2016)

Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells
por: Handa, Haruka, et al.
Publicado: (2018)

Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
por: Hashimoto, Ari, et al.
Publicado: (2022)

Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma
por: Menju, Toshi, et al.
Publicado: (2011)

The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis(†)
por: Sabe, Hisataka, et al.
Publicado: (2009)

GEP100-Arf6-AMAP1-Cortactin Pathway Frequently Used in Cancer Invasion Is Activated by VEGFR2 to Promote Angiogenesis
por: Hashimoto, Ari, et al.
Publicado: (2011)

Co-Overexpression of GEP100 and AMAP1 Proteins Correlates with Rapid Local Recurrence after Breast Conservative Therapy
por: Kinoshita, Rumiko, et al.
Publicado: (2013)

Necessity of p53-binding to the CDH1 locus for its expression defines two epithelial cell types differing in their integrity
por: Oikawa, Tsukasa, et al.
Publicado: (2018)

EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial–mesenchymal transition
por: Hirano, Mariko, et al.
Publicado: (2008)

ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance
por: Hashimoto, A, et al.
Publicado: (2016)

Rab5c promotes AMAP1–PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion
por: Onodera, Yasuhito, et al.
Publicado: (2012)

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
por: Nardi, Francesca, et al.
Publicado: (2023)

Pag3/Papα/Kiaa0400, a Gtpase-Activating Protein for Adp-Ribosylation Factor (Arf), Regulates Arf6 in Fcγ Receptor–Mediated Phagocytosis of Macrophages
por: Uchida, Hiroshi, et al.
Publicado: (2001)

High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue
por: Otsuka, Yutaro, et al.
Publicado: (2016)

ARF1 recruits RAC1 to leading edge in neutrophil chemotaxis
por: Mazaki, Yuichi, et al.
Publicado: (2017)

Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments
Publicado: (1995)

Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases
por: Takada, Shingo, et al.
Publicado: (2022)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe
por: Onodera, Yasuhito, et al.
Publicado: (2018)

Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis
por: Best, Sarah A., et al.
Publicado: (2020)

GBF1 bears a novel phosphatidylinositol-phosphate binding module, BP3K, to link PI3Kγ activity with Arf1 activation involved in GPCR-mediated neutrophil chemotaxis and superoxide production
por: Mazaki, Yuichi, et al.
Publicado: (2012)

Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms
por: Qi, Chen-Feng, et al.
Publicado: (2012)

High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients
por: Sato, Hiroki, et al.
Publicado: (2014)

Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor
por: Sugihara, Eiji, et al.
Publicado: (2011)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Succinyl-CoA-based energy metabolism dysfunction in chronic heart failure
por: Takada, Shingo, et al.
Publicado: (2022)

Germinal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
por: Mullins, Chelsea D., et al.
Publicado: (2013)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
por: Mainwaring, Oliver J., et al.
Publicado: (2023)

ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity
por: Hashimoto, Ari, et al.
Publicado: (2023)

Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay
por: Yoshimi, Kazuto, et al.
Publicado: (2012)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

Biological significance of KRAS mutant allele expression in ovarian endometriosis
por: Yachida, Nozomi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n57gtqaa4lj8hoptahpn9u2cg5